Bortezomib: all 701 studies that test it
Page 5 of 8. Open to participants first (47), then studies with results posted, then the rest; newest registration first within each.
- Bortezomib Maintenance in High Risk DLBCLStatus unknownNCT01965977Phase 2
- A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple MyelomaCompletedNCT01965353Phase 1
- Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple MyelomaTerminatedNCT01954784Phase 1
- Proteasome Inhibition in Acute Promyelocytic LeukemiaStatus unknownNCT01950611Phase 2
- Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT01936090Phase 1
- Maintenance Therapy With Subcutaneous BortezomibCompletedNCT01913730Phase 2
- Study to Evaluate Optimized Retreatment and Prolonged Therapy With BortezomibCompletedNCT01910987Phase 3
- An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular LymphomaTerminatedNCT01902862Phase 2
- Bortezomib in Late Antibody-mediated Kidney Transplant RejectionCompletedNCT01873157Phase 2
- Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT01863550Phase 3
- Proteasomal Inhibition for Patients With Mis-sense Mutated DysferlinTerminatedNCT01863004Phase 1
- Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid LeukemiaActive, not recruitingNCT01861314Phase 1
- Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.CompletedNCT01848132Phase 2
- Desensitization With Bortezomib Before a Living Kidney DonationStatus unknownNCT01842074Phase 4
- VELCADE® Plus Rituximab in Non Hodgkin's Follicular LymphomaCompletedNCT01830465Phase 2
- A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard TherapyCompletedNCT01794507Phase 1
- Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's MacroglobulinemiaCompletedNCT01788020Phase 3
- First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDDTerminatedNCT01728259Phase 1
- Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)CompletedNCT01720875Phase 2
- Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaCompletedNCT01711528Phase 1
- Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin DiseaseCompletedNCT01696474Phase 2
- Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin LymphomaActive, not recruitingNCT01695941Phase 1
- Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple MyelomaWithdrawnNCT01680796Phase 1
- Bortezomib in Patients With Chronic Graft Versus Host DiseaseCompletedNCT01672229Phase 1
- Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib MaintenanceWithdrawnNCT01647165Phase 2
- Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT01633645Phase 2
- Autophagy Induction After Bortezomib for MyelomaCompletedNCT01594242Early Phase 1
- Randomised Trial in Waldenstrom's MacroglobulinaemiaCompletedNCT01592981Phase 2
- Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple MyelomaTerminatedNCT01537861Early Phase 1
- Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple MyelomaCompletedNCT01530594Phase 3
- Bortezomib Consolidation TrialCompletedNCT01517724Phase 2
- Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)CompletedNCT01504776Phase 1
- Lapatinib and Bortezomib in Patients With Advanced MalignanciesTerminatedNCT01497626Phase 1
- Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT01497093Phase 1
- Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory MyelomaCompletedNCT01495351Phase 1
- Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple MyelomaWithdrawnNCT01492881Phase 2
- A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT01485835Phase 1
- ACVDL Treatment for Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01481194Phase 2
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic TransplantationCompletedNCT01460420Phase 1/2
- Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCLStatus unknownNCT01449344Phase 3
- Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck CancerCompletedNCT01445405Phase 1
- Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) PatientsCompletedNCT01440582Phase 1
- Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)Status unknownNCT01439750Phase 1
- Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma MultiformeCompletedNCT01435395Phase 1
- Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple MyelomaCompletedNCT01428492Phase 1
- Clonal Deletion on Living-Relative Donor Kidney TransplantationStatus unknownNCT01408797Phase 1/2
- Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)CompletedNCT01394354Phase 1/2
- Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell LymphomaWithdrawnNCT01386398Phase 3
- Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple MyelomaCompletedNCT01376401Phase 2
- Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT01359657Phase 1
- SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple MyelomaWithdrawnNCT01329289Phase 2
- Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell LeukemiaStatus unknownNCT01328236Phase 2
- A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With BortezomibCompletedNCT01324596Phase 3
- Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and EtoposideTerminatedNCT01300793Phase 1
- Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL)CompletedNCT01273844Not applicable
- A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaWithdrawnNCT01266811Phase 3
- Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 StudyStatus unknownNCT01255527Phase 1/2
- Efficacy Study of PAD and TAD in Newly Diagnosed Multiple MyelomaStatus unknownNCT01249690Phase 4
- Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple MyelomaCompletedNCT01233895Phase 1
- Frontline Therapy in de Novo Multiple Myeloma Patients Under 65CompletedNCT01206205Phase 2
- Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 YearsCompletedNCT01191060Phase 3
- Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple MyelomaCompletedNCT01183949Phase 1/2
- A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or LymphomaCompletedNCT01171092Early Phase 1
- Velcade for Proliferative Lupus NephritisWithdrawnNCT01169857Phase 4
- Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple MyelomaCompletedNCT01168804Phase 2
- Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic CancerCompletedNCT01164709Phase 1
- Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic LeukemiaWithdrawnNCT01162031Phase 2
- Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)Status unknownNCT01158105Phase 2
- VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)Status unknownNCT01134484Phase 3
- Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell LymphomaCompletedNCT01129180Phase 1
- Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01127009Phase 1
- Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MMCompletedNCT01114282Phase 1
- Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)Status unknownNCT01114048Phase 2
- Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell LymphomaTerminatedNCT01111188Phase 1
- Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal FailureCompletedNCT01084837Phase 2
- An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant MelanomaCompletedNCT01078961Phase 1
- Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic SyndromeCompletedNCT01075425Phase 1
- Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT01074411Phase 1
- Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma PatientsCompletedNCT01063179Phase 3
- S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaWithdrawnNCT01055301Phase 2
- Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's MacroglobulinemiaCompletedNCT01046006Phase 2
- Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple MyelomaCompletedNCT01045681Phase 2
- A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01038388Phase 1
- Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi SarcomaCompletedNCT01016730Phase 1
- Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal MesotheliomaStatus unknownNCT00996385Phase 2
- Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple MyelomaWithdrawnNCT00995059Phase 1/2
- Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and LymphomaCompletedNCT00994500Phase 1
- Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma PatientsTerminatedNCT00984828Phase 2/3
- Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple MyelomaCompletedNCT00972712Phase 1
- Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT00963274Phase 1
- Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell LymphomaCompletedNCT00901147Phase 2
- Study of Erlotinib in Combination With BortezomibCompletedNCT00895687Phase 1
- Panobinostat/Velcade in Multiple MyelomaTerminatedNCT00891033Phase 1
- Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior TherapyActive, not recruitingNCT00871013Phase 2
- UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete RemissionActive, not recruitingNCT00869232Phase 2
- Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCTCompletedNCT00861250Phase 2/3
- Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms MacroglobulinemiaCompletedNCT00832234Phase 2
- PAD. ICORG 05-01, V11CompletedNCT00814541Phase 2
- Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström MacroglobulinemiaCompletedNCT00777738Phase 2
- Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving RadioimmunotherapyCompletedNCT00777114Phase 1